CLINICAL STUDY PROTOCOL  
 
 
An Analysis  of the Efficacy  of a Pre- 
Emptive Multimodal Pain Regimen in 
Reducing Acute Post -Operative Pain and 
Narcotic Pain Medication Requirements 
in Spi[INVESTIGATOR_181315]  
[ADDRESS_436605], Apt -3S 
MINEOLA,  NY, [ZIP_CODE],  United  States  
 
Protocol  Version  
May 12, 2020  
version  2 
 
 
 
 
 
 
 
 
 
 
Confidentiality  Statement:  Study ID: [REMOVED]  
Study Number: 20 -[ZIP_CODE] 
PI: [INVESTIGATOR_351164],  MD 
Protocol Number  May 12, 2020 - version 2 
2  
 Study  Personnel  
Investigator  Muhammad  Tariq  
NYU  Winthrop  Hospi[INVESTIGATOR_351165]: [PHONE_7264]  
Email:  [EMAIL_6750]  
Protocol Number  May 12, 2020 - version 2 
3  
 Synopsis  
 
 
Primary  Objective  
 
Aim 1: Determine  pain control  post-operatively after  elective spi[INVESTIGATOR_351166] 2:  Determine  patient  variables  significantly  associated  with post-operative  pain 
control  
 
 
Aim 3:  Determine  operative  variables  significantly  associated  with post-operative  pain 
control  
 
 
Aim 4:  Determine  long term  outcomes  and complication  rates  after  pre-emptive  MMA 
regimen implementation  
Study  Duration  
 
Expected  Duration:  2020  to 2022  
Study  Design  
 
Prospective  Cohort  Study  
Study  Population  
 
Adult  patients  undergoing  elective  spi[INVESTIGATOR_351167] 12, 2020 - version 2 
4  
  
Number  of Participants  
 
At a significance  level  of 5%, in order  to achieve  80%  power  for detecting  a 1 point  mean 
difference  in VAS  pain scores [1], we would  need  a sample  of 31 patients  to assess  the 
primary outcome. Adjusting by [CONTACT_3450] 5% to account for patients that are found 
ineligible retrospectively, the total sample size required is 33 patients for the primary 
outcome.  
Furthermore,  additional  analyses  to fulfill  Aims  2-4 would  require  a larger  sample  size and 
would constitute separate studies based on final sample size achieved  
 
[1] Using  the reported  control  group  VAS  scores  by [CONTACT_316832]. of 8.[ADDRESS_436606] 
deviation of 2  
Number  of Study  Sites  
 
The study  will be conducted  out of NYU  Winthrop  hospi[INVESTIGATOR_351168].  
Primary  Outcome  Variables  
 
Aim 1: Determine  pain control  post-operatively after  elective spi[INVESTIGATOR_351169]:  length  of stay in PACU,  opi[INVESTIGATOR_351170],  drain  output, 
transfusion rates, and hospi[INVESTIGATOR_7577].  
Secondary  and Exploratory  Outcome  Variables  
 
Aim 2: Determine  patient  variables  significantly  associated  with above  outcomes  
 
 
The following variables will be considered: age, gender, race, comorbidities, pain 
medication  use prior  to surgery  (including  dose  and number  of years  used),  history  of 
Protocol Number  May 12, 2020 - version 2 
5  
  
seeing  a pain management  physician,  history  of psychological  illnesses,  demographic 
history, use of ambulatory aids and activity level at baseline  
 
 
Aim 3: Determine  operative  variables  significantly  associated  with above  outcomes  
 
 
The following  variables  will be considered:  primary  vs revision  surgery,  surgical  site, 
number of spi[INVESTIGATOR_351171], length of surgery, use of intr a-operative dexamethasone, 
blood loss, ASA score  
 
 
Aim 4:  Determine  long term  outcomes  and complication  rates  after  pre-emptive  MMA 
regimen implementation  
 
Determine  patient  reported  VAS  pain  scores  at [ADDRESS_436607] -operatively 
Determine  rate of surgical  complications  including  surgical  site infection,  readmission, 
pseudoarthrosis/lack of fusion rates, hardware complication, revision surgery, 
neurolo gical deficit  
Visit  Schedule  Table  (Optional)  
Study  Flow  Chart  (optional)  
Protocol Number  May 12, [ADDRESS_436608] -Operative  Pain  and Narcotic  Pain  Medication  Requirements  in Spi[INVESTIGATOR_351172]3 
Primary  Objective  ................................ ................................ ................................ ................................  3 
Secondary  Objectives  ................................ ................................ ................................ ........................  3 
Study  Duration  ................................ ................................ ................................ ................................ .... 3 
Study  Design ................................ ................................ ................................ ................................ ....... 3 
Study  Population  ................................ ................................ ................................ ................................  3 
Number  of Participants ................................ ................................ ................................ ......................  3 
Number  of Study  Sites  ................................ ................................ ................................ ......................  3 
Primary  Outcome  Variables  ................................ ................................ ................................ .............  3 
Secondary  and Exploratory  Outcome  Variables  ................................ ................................ ..........  3 
Visit Schedule  Table  (Optional)  ................................ ................................ ................................ ....... 3 
Abbreviations ................................ ................................ ................................ ................................ ....... 6 
Glossary  of Terms  ................................ ................................ ................................ ..............................  7 
1 - Introduction  ................................ ................................ ................................ ......................  11 
1.1 Introductory  Statement  ................................ ................................ ................................ ...........  11 
2 - Background  ................................ ................................ ................................ ......................  12 
2.1.1  Preclinical  Experience  ................................ ................................ ................................ ...........  12 
2.1.2  Clinical Experience  ................................ ................................ ................................ ..........................  12 
2.2 Background/prevalence  of research  topic  ................................ ................................ ..........  14 
3 - Rationale/Significance  ................................ ................................ ................................ . 15 
3.1 Problem  Statement  ................................ ................................ ................................ ...................  15 
3.2 Purpose  of Study/Potential  Impact  ................................ ................................ .......................  15 
3.3.1  Potential  Risks ................................ ................................ ................................ ................................  15 
3.3.2  Potential  Benefits  ................................ ................................ ................................ ........................... 16 
4 - Study  Objectives  ................................ ................................ ................................ ...........  17 
4.1 Hypothesis  ................................ ................................ ................................ ................................ . 17 
4.2 Primary  Objective  ................................ ................................ ................................ ......................  17 
4.3 Secondary  Objectives  ................................ ................................ ................................ ..............  17 
5 - Study  Design  ................................ ................................ ................................ ..................  18 
5.1 General  Design  Description ................................ ................................ ................................ .... 18 
5.1.1  Study  Date  Range  and Duration ................................ ................................ ................................ . 18 
5.1.2  Number  of Study  Sites  ................................ ................................ ................................ .................. 18 
5.2 Outcome  Variables  ................................ ................................ ................................ ..................  18 
5.2.1  Primary  Outcome  Variables  ................................ ................................ ................................ .......... 19 
5.2.2  Secondary  and Exploratory  Outcome  Variables  ................................ .............................  19 
5.3 Study  Population  ................................ ................................ ................................ ......................  19 
5.3.1  Number  of Participants  ................................ ................................ ................................ ................... 19 
5.3.2  Eligibility  Criteria/Vulnerable  Populations  ................................ ................................ ................. [ADDRESS_436609]/New  Drug  ................................ ................................ .........  21 
Protocol Number  May 12, 2020 - version 2 
9  
 6.1.2  Dosage,  Admin,  Schedule  ................................ ................................ ................................ ............ 21 
6.1.3  Method  of Assignment/Randomization  ................................ ................................ ...............  21 
6.1.4  Blinding  and Procedures  for Unblinding  ................................ ................................ ...........  21 
6.1.5  Packaging/Labelling  ................................ ................................ ................................ ....................... 21 
6.1.6  Storage  Conditions  ................................ ................................ ................................ ......................... 21 
6.1.7  Concomitant  therapy  ................................ ................................ ................................ ..................... 21 
6.1.8  Restrictions  ................................ ................................ ................................ ................................ ......22 
6.2 Assessments  ................................ ................................ ................................ ..............................  22 
6.2.1  Efficacy  ................................ ................................ ................................ ................................ ............. 22 
6.2.2  Safety/Pregnancy -related  policy  ................................ ................................ ................................ .23 
[IP_ADDRESS]  Adverse  Events  Definition  and Reporting  ................................ ................................ .............. 23 
6.2.3  Pharmacokinetics  ................................ ................................ ................................ ..................  23 
6.2.4  Biomarkers  ................................ ................................ ................................ .............................  23 
6.3 Study  Procedures  ................................ ................................ ................................ .....................  23 
6.3.1  Study  Schedule ................................ ................................ ................................ ............................... 23 
6.3.2  Informed  Consent  ................................ ................................ ................................ .......................... 23 
6.3.3  Screening  ................................ ................................ ................................ ................................ .........24 
6.3.4  Recruitment,  Enrollment  and Retention  ................................ ................................ .........  24 
6.3.5  On Study  Visits  ................................ ................................ ................................ ............................... 24 
6.3.6  End of Study  and Follow -up ................................ ................................ ................................ .........24 
6.3.7  Removal  of subjects ................................ ................................ ................................ ....................... 24 
6.4 Statistical  Method ................................ ................................ ................................ ....................  24 
6.4.1  Statistical  Design  ................................ ................................ ................................ ........................... 25 
6.4.2  Sample  Size Considerations  ................................ ................................ ................................ .........25 
6.4.3  Planned  Analyses  ................................ ................................ ................................ ...................  25 
[IP_ADDRESS]  Primary  Analyses  ................................ ................................ ................................ ..............  25 
[IP_ADDRESS]  Secondary  Objectives  Analy ses ................................ ................................ .....................  25 
[IP_ADDRESS]  Safety/Pregnancy -related  policy  ................................ ................................ ....................  25 
[IP_ADDRESS]  Analysis  of Subject  Characteristics  ................................ ................................ .................  25 
[IP_ADDRESS]  Interim  Analysis ................................ ................................ ................................ .................  26 
[IP_ADDRESS]  Health  economic  evaluation  ................................ ................................ ............................  26 
[IP_ADDRESS]  Other  ................................ ................................ ................................ ................................ .... 26 
6.4.4  Subsets  and Covariates  ................................ ................................ ................................ ................ 26 
6.4.5  Handling  of Missing  Data  ................................ ................................ ................................ .............. 26 
7 - Trial  Administration  ................................ ................................ ................................ ..... 27 
7.1 Ethical Considerations:  Informed  Consent/Assent and  HIPAA  Authorizatio n ...............  [ADDRESS_436610]  (IRB)  Review  ................................ ................................ ............  [ADDRESS_436611]  Confidentiality  ................................ ................................ ................................ ............  27 
7.4 Deviations/Unanticipated  Problems  ................................ ................................ ....................  27 
7.5 Data  Collection  ................................ ................................ ................................ .........................  27 
7.6 Data  Quality  Assurance  ................................ ................................ ................................ ..........  27 
7.7 Study  Records  ................................ ................................ ................................ ...........................  27 
7.8 Access  to Source  ................................ ................................ ................................ ......................  27 
7.9 Data  or Specimen  Storage/Security  ................................ ................................ .....................  [ADDRESS_436612]-operative pain control is vital; especially given the recent rising healthcare urgency to 
limiting opi[INVESTIGATOR_351173]. Historically, post -operative pain control 
regimens have relied heavily on opi[INVESTIGATOR_351174]3. However,  several  limitations  exist  to this model  of pain control  including 
poor pain control and a host of opi[INVESTIGATOR_351175]35. 
Recently significant interest has been brought to the utilization of multimodal analgesia 
(MMA)15. MMA takes advantage of the synergistic effect of multiple pain medications that 
act through  different  mechanisms  of actions  to target  pain more  effectively.  Several  studies 
have highlighted the efficacy of such regimens and have proven that these regimens are 
safe5,6,8,12,15,24,31,37. 
Furthermore, the pre -emptive administration of pain  medications has been believed to be 
more efficacious in controlling post -operative pain36. Pre -emptive control of pain is thought 
to mitigate  or halt central  nervous  system  sensitization  (which  includes  prolonged  changes) 
as a result of noxious stimuli su ch as surgery36. Therefore, we sought to evaluate the 
efficacy of a pre -emptive MMA pain regimen in controlling post -operative pain in a 
community hospi[INVESTIGATOR_6885].  
Protocol Number  May 12, [ADDRESS_436613] commonly used non -opi[INVESTIGATOR_11595] s utilized exerts its 
effects though cyclooxygenase (COX) inhibition. Multiple studies have demonstrated 
improved pain control and reduced opi[INVESTIGATOR_351176]29,33. As such  acetaminophen  remains  a cornerstone  in 
most multimodal pain regimens.  
Nonsteroidal anti -inflammatory (NSAID) medications are another commonly utilized 
analgesic choice. They exert their anti -inflammatory and analgesic effects via COX 
inhibition therefore b locking prostaglandin production. Although COX1 are ubiquitous 
throughout the body, COX2 enzymes are more specific to inflammatory tissues. Specific 
COX2  inhibitors  were  developed  in order  to minimize  adverse  effects  of COX1  inhibition  (ie 
gastric mucosa d amage and platelet dysfunction). However, there has been controversy 
over  the use of NSAIDs  in spi[INVESTIGATOR_351177],  pseudoarthrosis,  and 
bleeding/hematoma  formation.  A number  of studies  have  shown  higher  nonunion  rates  in a 
dose  dependent  manner  with the use of NSAIDs19,39. Nevertheless,  recent  studies  highlight 
that COX2  inhibitors  as well as NSAIDs  used  in lower  doses  prove  to be efficacious  for pain 
control and may not carry the same adverse effects as previously thought10,11,[ADDRESS_436614]  looked  at MMA  efficacy  in spi[INVESTIGATOR_351178]-emptively (ie pre - 
operatively)1,13,14,16,36. 
Garcia et al. report their findings of a preemptive MMA regimen with 22 patients 
undergoing lumbar laminectomy surgery8. In this randomized control trial (RCT), patients 
received either IV morphine only or MMA regimen consisting of [ADDRESS_436615]-op. They 
found  that compared  to the IV morphine  group,  the MMA  group  had lower  VAS  pain  scores 
at all time points, a 58% reduction in morphine consumption and earlier oral food intake. 
No difference in intra -operative blood loss was noted.  
 
Another  RCT  by [CONTACT_137219]. looked  at preemptive  MMA  efficacy  in single  level  lumbar  fusion 
surgery  in [ADDRESS_436616] received preemptive analgesics; COX2 inhibitors with or without 
gabapentin/pregabalin.  [ADDRESS_436617]-op. Furthermore,  EQ-5D activity,  depression/anxiety,  and self-care  also 
improved significantly in the preemptive group at [ADDRESS_436618] -op MMA after spi[INVESTIGATOR_351179] 85 and 200 patients 
respectively22,26. They  also note  improved  pain control  and lower  opi[INVESTIGATOR_351180].  
Protocol Number  May 12, 2020 - version 2 
14  
 Unfortunately,  the long  term  outcomes  including  fusion  rates  and complications  such  as 
pseudarthrosis were not found in our review to be reported by [CONTACT_351199].  
 
 
 
 
2.2 Background/prevalence  of research  topic  
Protocol Number  May 12, 2020 - version 2 
15  
 3 - Rationale/Significance  
3.[ADDRESS_436619]-operative pain control. Pain leads to a number of adverse effects on physical, 
emotional, and social health as well as to short and long term outcomes32. 
 
 
3.2 Purpose  of Study/Potential  Impact  
 
Adequate  and effective  pain control  leads  to lower  risk of complications,  greater  patient 
satisfaction, and earlier mobility, rehab as well as recovery from surgery17,18,25,31. 
Traditionally pain control has focused on opi[INVESTIGATOR_351181] -operatively3. However, recent advances in pain control  research have 
brought up a shift in paradigm to targeting pain earlier1,16,36. Pain leads to a cascade of 
neuronal activation as well as some changes that may be long term in the central nervous 
system36. Therefore blocking the pain pathway earlier prior to prevent is thought to prevent 
central sensitization to pain and prevent these long term changes in the central nervous 
system. Furthermore, this paradigm of targeting pain before it occurs is thought to lead to 
more  effective  pain control  as well as reduce the opi[INVESTIGATOR_351182]-operative  pain 
control1,16. 
Utilizing  multiple  agents  to control  pain is conjectured  to work  in a synergistic  manner, 
described  as multimodal  analgesia(MMA)37. This allows  not only a strategy  to target  pain 
more  effectively  through  numerous  distinct  pathways  but also allows  the use of lower  doses 
of each  individual  analgesic  therefore  mitigating  adverse  effects  of each  medication12,15,28. 
A growing  body  of evidence  supports  the utility  of MMA  in spi[INVESTIGATOR_351183]30. 
Therefore  significant  interest  exists  in optimizing  MMA  protocols  especially  prior  to the 
onset  of pain  for treating  patients  undergoing  spi[INVESTIGATOR_351184]12,15,16,37. 
 
 
3.3.[ADDRESS_436620]-op period, improving o utcomes, and facilitating recovery after elective spi[INVESTIGATOR_79477].  
Protocol Number  May 12, 2020 - version 2 
17  
 4 - Study  Objectives  
4.1 Hypothesis  
 
Multimodal pain regimen (consisting of acetaminophen, celecoxib, gabapentin, and 
oxycodone) administered pre -operatively before elective spi[INVESTIGATOR_351185] -operatively as well as decreasing requirements of post -op 
opi[INVESTIGATOR_351186] a pre -operative pain regimen.  
 
 
4.2 Primary  Objective  
 
Aim 1: Determine  pain control  post-operatively after  elective spi[INVESTIGATOR_351183]  
 
 
 
 
 
 
4.3 Secondary  Objectives  
 
 
Aim 2: Determine  patient  variables  significantly  associated  with post-operative  pain control  
 
 
Aim 3:  Determine  operative  variables  significantly  associated  with post-operative  pain 
control  
 
 
Aim 4:  Determine  long term  outcomes  and complication  rates  after  pre-emptive  MMA 
regimen implementation  
Protocol Number  May 12, [ADDRESS_436621]- 
op oxycodone based pain control regimen given on an as needed basis. The treatment 
group outcomes will be compared to patients outside of the study including a historica l 
control group (receiving only post -op pain regimen) prior to the implementation of the new 
regimen.  
The studied  treatment  group  will receive  within  3 hours  before  surgery  an oral MMA 
regimen consisting of:  
 
Acetaminophen  [ADDRESS_436622]  (EMR)  with 
notation  of VAS  score  in RN documentation  in PACU  as well as EMR  record  of time of opi[INVESTIGATOR_351187]. The pre -op history and physical will be utilized for extracting 
demographic and clinical data. Finally, long term data will be requested from outpatient 
office  patient  records  at defined  time intervals.  Pain  medication  usage  will be reviewed  with 
prescriptions  given  / noted  in state  (ISTOP)  registries.  Complication  rates  will be assessed 
using  outpatient  records  as well as readmission/ER  documentation  in EMR.  
Measurement  reliability  is dependent  on accuracy  of data  reported  in EMR  and by [CONTACT_351200]. The use of standardized data collection procedures will limit any 
measurement bias that may be observed. Discretionary data outside the standardized 
collection criteria will not be collected. Potential confounders and effect modifiers are 
outlined in the study aims as the patient and treatment characteristics. Their influence will 
be statistically evaluated using stratified univariate and multivariate analyses.  
 
 
5.2.[ADDRESS_436623] 31 patients would be needed for the primary outcome. However, in the 
recruitment  period,  the goal would  be to include  as many participants  as possible  (100 -200) 
in order for the secondary and ancillary outcomes to be achieved for statistical subgroup 
analyses.  
 
 
5.3.2  Eligibility  Criteria/Vulnerable  Populations  
Eligibility  Criteria  will be assessed  by [CONTACT_978] [INVESTIGATOR_351188]. 
Inclusion Criteria:  
Protocol Number  May 12, 2020 - version 2 
20  
 Undergoing elective spi[INVESTIGATOR_351189] 18 years  
 
Exclusion  Criteria:  
 
History of neuromuscular disorders 
History of inflammatory arthropathies  
History  of spi[INVESTIGATOR_351190]: renal dysfunction, gastric ulcers, hepatic 
dysfunction,  coagulopathic/bleeding  disorders,  prior  adverse  or allergic  reactions  to any 
of the medications in the study  
Age less than  [ADDRESS_436624]/New  Drug  
 
All drugs  utilized  are well established  and FDA  approved.  They  are also currently  in 
common use.  
 
Acetaminophen (Tylenol) 
Celecoxib (Celebrex) 
Gabapentin (Neurontin)  
Oxycodone  10 mg Extended  Release  (Oxycontin)  
 
 
6.1.2  Dosage,  Admin,  Schedule  
 
The studied  treatment  group  will receive  within  3 hours  before  surgery  an oral MMA 
regimen consisting of:  
 
Acetaminophen  975 mg 
Celecoxib  200 mg 
Gabapentin  300 mg 
Oxycodone  10 mg Extended  Release  
 
 
6.1.3  Method  of Assignment/Randomization  
 
6.1.4  Blinding  and Procedures  for Unblinding  
 
6.1.5  Packaging/Labelling  
 
Included  in hospi[INVESTIGATOR_351191].  Administration  through  nursing  similar  to all drugs 
in the inpatient setting. No special packaging or labelling will be utilized.  
 
 
6.1.[ADDRESS_436625]  (EMR)  with 
notation  of VAS  score  in RN documentation  in PACU  as well as EMR  record  of time of opi[INVESTIGATOR_351187]. The pre -op history and physical will be utilized for extracting 
demographic and clinical data. Finally, long term data will be requested from outpatient 
office  patient  records  at defined  time intervals.  Pain  medication  usage  will be reviewed  with 
prescriptions  given  / noted  in state  (ISTOP)  registries.  Complication  rates  will be assessed 
using  outpatient  records  as well as readmission/ER  documentation  in EMR.  
 
 
 
6.2.[ADDRESS_436626] modifiers are 
outlined in the study aims as the patient and treatment characteristics. Their influence will 
be statistically evaluated using stratified univariate and multivariate analyses.  
The study  outcomes  of VAS  pain score  and opi[INVESTIGATOR_351192]/rescue  time will be calculated  as 
a mean  using  PACU  VAS  pain  scores  noted  in EMR  and time from  extubation  to when  opi[INVESTIGATOR_351193].  Comparison  to detect  a statistical  difference  of these  outcomes 
compared to historical control group will be done using student's t test. Furthermore,  
patient and treatment characteristics will be evalua ted using univariate and multivariate 
analyses  with cox proportional  hazards  regression  modeling.  Atypi[INVESTIGATOR_351194]. The sourc e of biostatistical expertise will come from the 
department biostatistician.  
Protocol Number  May 12, 2020 - version 2 
23  
  
6.2.2  Safety/Pregnancy -related  policy  
 
Pregnant  patients  are excluded  from  study.  
 
The risks of the MMA include drug hypersensitivity reactions or adverse effects of the 
medications. In order to minimize these risks a thorough pre -operative history would be 
conducted  and reviewed  to screen  for any known  allergies  as well as any health  conditions 
(ie liver or kidney disease) which would lead to higher risk of adverse effect s of the MMA 
medications.  Furthermore,  since  a single  dose  is use of the medication  it limits  medication 
exposure and risk of adverse effects.  
 
 
[IP_ADDRESS]  Adverse  Events  Definition  and Reporting  
 
Adverse events will be defined as any events not considered within the  realm of routine 
post-operative  course.  Adverse  events  will be monitored  in the post-operative  period  while 
in the hospi[INVESTIGATOR_351195].  Chart  review  from  all providers 
will be screened for adverse events until last follow -up to date.  
 
 
6.2.[ADDRESS_436627] from this study.  
Protocol Number  May 12, 2020 - version 2 
24  
 6.3.2  Informed  Consent  
 
Informed  consent  process  will be followed  per NYU  policy.  
 
Informed consent will be received from all patients included in the study. The information 
obtained will be of vital importan ce to the progression of the field and future treatment of 
patients.  Informed  consent  will be obtained  by [CONTACT_351201] [INVESTIGATOR_351196]. Informed consent process will be conducted with a thorough discussion of 
risks and benefit s of the study to the patients followed by [CONTACT_351202]. The consent will be obtained either in print or electronically (utilizing ipad 
resource common used for surgical consents). Consent will be obtained either at pre -op 
visit in the office or at check in to the hospi[INVESTIGATOR_307]. Privacy will be protected by [CONTACT_9377][INVESTIGATOR_351197] a safe and secure platform. Consent will be documented and recorded 
alongside the remaining patient variables in order to ensure consent is achieved f or all 
participants.  
 
 
6.3.[ADDRESS_436628] modifiers are 
outlined in the study aims as the patient and treatment characteristics. Their infl uence will 
be statistically evaluated using stratified univariate and multivariate analyses.  
The study  outcomes  of VAS  pain score  and opi[INVESTIGATOR_351192]/rescue  time will be calculated  as 
a mean  using  PACU  VAS  pain  scores  noted  in EMR  and time from  extubation  to when  opi[INVESTIGATOR_351193].  Comparison  to detect  a statistical  difference  of these  outcomes 
compared to historical control group will be done using student's t test. Furthermore,  
patient and treatment characteristics will be evalua ted using univariate and multivariate 
analyses  with cox proportional  hazards  regression  modeling.  Atypi[INVESTIGATOR_351194]. The sourc e of biostatistical expertise will come from the 
department biostatistician.  
 
 
6.4.2  Sample  Size  Considerations  
 
At a significance  level  of 5%, in order  to achieve  80%  power  for detecting  a 1 point  mean 
difference  in VAS  pain scores [1], we would  need  a sample  of 31 patients  to assess  the 
primary outcome. Adjusting by [CONTACT_3450] 5% to account for patients that are found 
ineligible retrospectively, the total sample size required is 33 patients. Furthermore, 
additional analyses to fulfill Aims 1 -4 would require a larger sample size and would 
constitute separate studies based on final sample size achieved.  
 
[1] Using  the reported  control  group  VAS  scores  by [CONTACT_316832].[ADDRESS_436629] 
deviation of 2  
 
 
6.4.3  Planned  Analyses  
 
[IP_ADDRESS]  Primary  Analyses  
 
[IP_ADDRESS]  Secondary  Objectives  Analyses  
 
[IP_ADDRESS]  Safety/Pregnancy -related  policy  
Protocol Number  May 12, 2020 - version 2 
26  
 [IP_ADDRESS]  Analysis  of Subject  Characteristics  
 
[IP_ADDRESS]  Interim  Analysis  
 
[IP_ADDRESS]  Health  economic  evaluation  
 
[IP_ADDRESS]  Other  
 
6.4.4  Subsets  and Covariates  
 
see aims  and statistical  design.  
 
 
6.4.5  Handling  of Missing  Data  
 
Given the acute and short term nature of study's primary outcome. Missing data is 
expected  to be minimal.  However,  if data  is missing  then  statistically  valid  analyses  under 
the primary missing -data assumptions would be conducted to account for it.  
Protocol Number  May 12, 2020 - version 2 
27  
 7 - Trial  Administration  
7.1 Ethical Considerations: Informed Consent/Assent and HIPAA 
Authorization  
 
In addition to IRB approval and guidelines, all patient data will be kept protected under 
HIPAA guidelines. Informed consent will be obtained from a ll patients. Patients will be 
treated  in a professional  manner  consistent  with standard  of care.  All data  will be handled 
in a secure and professional manner. No financial or other incentives will be provided to 
participants.  
 
 
7.[ADDRESS_436630]  (IRB)  Review  
 
7.[ADDRESS_436631]  Confidentiality  
 
7.4 Deviations/Unanticipated  Problems  
 
7.[ADDRESS_436632]  (EMR)  with 
notation  of VAS  score  in RN documentation  in PACU  as well as EMR  record  of time of opi[INVESTIGATOR_351187]. The pre -op history and physical will be utilized for extracting 
demographic and clinical data. Finally, long term data will be requested from outpatient 
office  patient  records  at defined  time intervals.  Pain  medication  usage  will be reviewed  with 
prescriptions  given  / noted  in state  (ISTOP)  registries.  Complication  rates  will be assessed 
using  outpatient  records  as well as readmission/ER  documentation  in EMR.  
 
 
 
7.[ADDRESS_436633] modifiers are 
outlined in the study aim s as the patient and treatment characteristics. Their influence will 
be statistically evaluated using stratified univariate and multivariate analyses.  
 
 
7.7 Study  Records  
Protocol Number  May 12, 2020 - version 2 
28  
 7.8 Access  to Source  
 
7.9 Data  or Specimen  Storage/Security  
 
Data  will be stored  in a password -protected  Microsoft  Excel  file stored  on NYU  network 
drive.  
 
 
7.10  Retention of Records  
 
Records  will be retained  until 1 year  from  the conclusion  of the study.  
 
 
7.11  Study  Monitoring  
 
7.12  Data  Safety  Monitoring  Plan  
 
Primary  oversight  of the study  will be done  by [CONTACT_978] [INVESTIGATOR_351198],  following, 
and reporting of AEs from study participants. Secondary monitoring will be done by [CONTACT_351203]. Furthermore, systematic periodic review of data and AEs 
will be don e on a monthly basis. The accumulated data will include patient pain variables 
collected in the hospi[INVESTIGATOR_307], patient clinical information in EMR, and patient follow -up data.  
Adverse events will be noted and recorded at follow -up visits and include any describ ed 
(see drug package inserts) or undescribed events noted by [CONTACT_351204]. These 
events  will be reported  to the IRB as soon  as possible  or at the monthly  review.  The study 
will be stopped if any unexpected or adverse events not previously reported for the MMA 
are noted.  A summary  of AEs,  deviations,  and report  of the outcomes  of these  data  safety 
monitoring  reviews  will be submitted  to the IRB annually  with the Continuation  Submission  
 
 
7.[ADDRESS_436634]  Policy  
 
7.17  Funding  Source  
Protocol Number  May 12, 2020 - version 2 
29  
 N/A 
 
 
7.[ADDRESS_436635] and writing process.  
Protocol Number  May 12, 2020 - version 2 
30  
 Appendices  
 
Appendix  # Title  Section  Topic  
1 Acetaminophen 
Package Insert  6 Methods  6.1.5  Packaging/L 
abelling  
2 Gabapentin 
Package  Insert  6 Methods  6.1.5  Packaging/L 
abelling  
3 Oxycodone 
Package  Insert  6 Methods  6.1.5  Packaging/L 
abelling  
4 Celecoxib 
Package  Insert  6 Methods  6.1.5  Packaging/L 
abelling  
5 REFERENCES  7 Trial 
Administration  7.18 Publication 
Plan  
Protocol Number  May 12, 2020 - version 2 
31  
  
References  